Review
doi: 10.1080/09540260802095123.
Cognitive and behavioural impairment in Parkinson's disease
Affiliations
- PMID: 18925485
- DOI: 10.1080/09540260802095123
Item in Clipboard
Review
Cognitive and behavioural impairment in Parkinson's disease
Int Rev Psychiatry.
2008 Aug.
Abstract
Although Parkinson's disease (PD) has been considered to primarily affect motor abilities, increasing emphasis is being placed on cognitive and behavioural impairment in this disorder. Depression, dementia, psychosis and impulse control disorders have a major impact on quality of life for both patients and families. This article reviews cognitive and behavioural disturbances in PD and their relation to affective and motor symptoms, treatment of dementia associated with PD, and treatment approaches to psychosis in PD. We also discuss similarities between the dementia of PD and dementia with Lewy bodies.
Similar articles
-
The neuropsychiatry of Parkinson's disease and related disorders.Psychiatr Clin North Am. 2004 Dec;27(4):801-25. doi: 10.1016/j.psc.2004.07.001. Psychiatr Clin North Am. 2004. PMID: 15550293 Review.
-
Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications.Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1009-13. doi: 10.1016/j.pnpbp.2011.02.002. Epub 2011 Feb 13. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 21324349
-
Treatment of advanced Parkinson's disease.Expert Rev Neurother. 2006 Aug;6(8):1181-97. doi: 10.1586/14737175.6.8.1181. Expert Rev Neurother. 2006. PMID: 16893346 Review.
-
The neuropsychiatry of Parkinson's disease.Minerva Med. 2005 Jun;96(3):155-73. Minerva Med. 2005. PMID: 16175159 Review.
-
[Emotional and cognitive disorders in Parkinson disease].Tidsskr Nor Laegeforen. 1998 Oct 20;118(25):3959-63. Tidsskr Nor Laegeforen. 1998. PMID: 9830342 Review. Norwegian.
Cited by
-
The dopamine and cAMP regulated phosphoprotein, 32 kDa (DARPP-32) signaling pathway: a novel therapeutic target in traumatic brain injury.Exp Neurol. 2011 Jun;229(2):300-7. doi: 10.1016/j.expneurol.2011.02.013. Epub 2011 Mar 1. Exp Neurol. 2011. PMID: 21376040 Free PMC article.
-
Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease.Brain Sci. 2024 Jul 31;14(8):776. doi: 10.3390/brainsci14080776. Brain Sci. 2024. PMID: 39199470 Free PMC article. Review.
-
Profile of cognitive impairment in Parkinson's disease.Brain Pathol. 2010 May;20(3):640-5. doi: 10.1111/j.1750-3639.2010.00373.x. Brain Pathol. 2010. PMID: 20522089 Free PMC article. Review.
-
The risky business of dopamine agonists in Parkinson disease and impulse control disorders.Behav Neurosci. 2011 Aug;125(4):492-500. doi: 10.1037/a0023795. Behav Neurosci. 2011. PMID: 21604834 Free PMC article.
-
Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.Neurotox Res. 2011 Feb;19(2):211-34. doi: 10.1007/s12640-010-9190-2. Neurotox Res. 2011. PMID: 20393891 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
